← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
pertuzumab
L01FD02
Forms & Strengths
- 420 mg/14 mL (30 mg/mL) solution for injection
- 420 mg/14 mL (30 mg/mL) solution in a single-dose vial
Adult Dosing
- 840 mg loading dose, then 420 mg every 3 weeks
- Administer as an IV infusion over 60 minutes
- Subsequent infusions may be administered over 30-60 minutes
Pediatric Dosing
- Not approved for use in pediatric patients
- No established dose for patients under 18 years
Indications
- HER2-positive metastatic breast cancer
- Neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer
- Adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence
Mechanism of Action
- Monoclonal antibody targeting the extracellular dimerization domain of HER2
- Prevents receptor dimerization, inhibiting signaling pathways involved in cell proliferation and survival
Contraindications
- Hypersensitivity to pertuzumab or excipients
- Not contraindicated in pregnancy, but use with caution due to potential fetal harm
Adverse Reactions
- Diarrhea
- Fatigue
- Rash
- Mucosal inflammation
- Neutropenia
- Leukopenia
- Anemia
- Infusion-related reactions
Drug Interactions
- Trastuzumab: increased cardiotoxicity risk when used concomitantly
- Docetaxel: no significant pharmacokinetic interactions, but increased risk of neutropenia
Curated Content: Needs Vetting Before Put to Clinical Use